These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 17519792

  • 1. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
    Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Transplantation; 2007 May 27; 83(10):1389-92. PubMed ID: 17519792
    [Abstract] [Full Text] [Related]

  • 2. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 3. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Aug 27; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.
    Transplant Proc; 2008 Jun 27; 40(5):1541-4. PubMed ID: 18589147
    [Abstract] [Full Text] [Related]

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 6. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E.
    Liver Transpl; 2007 May 27; 13(5):658-64. PubMed ID: 17457887
    [Abstract] [Full Text] [Related]

  • 7. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y.
    Transplant Proc; 2009 May 27; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [Abstract] [Full Text] [Related]

  • 8. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, Egbuna O, Rodrigue JR, Chudzinski RE, Goldfarb-Rumyantzev AS, Hanto DW, Curry MP.
    Clin Transplant; 2009 May 27; 23(6):887-96. PubMed ID: 19681971
    [Abstract] [Full Text] [Related]

  • 9. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD, Bittencourt VB, Alves AB, Garcia VD, Tumelero A, Antonello JS, Malheiros D.
    Transplant Proc; 2006 May 27; 38(6):1901-3. PubMed ID: 16908317
    [Abstract] [Full Text] [Related]

  • 10. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 27; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 11. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec 27; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 12. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 13. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 15. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.
    Artif Organs; 2010 Aug 15; 34(8):E230-7. PubMed ID: 20618227
    [Abstract] [Full Text] [Related]

  • 16. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattström C.
    Clin Transplant; 2006 Aug 15; 20(3):336-9. PubMed ID: 16824151
    [Abstract] [Full Text] [Related]

  • 17. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED.
    Transplantation; 2006 Aug 15; 82(3):368-74. PubMed ID: 16906035
    [Abstract] [Full Text] [Related]

  • 18. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct 15; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 15; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 20. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.